O	0	7	Surgery
O	8	17	following
O	18	29	neoadjuvant
O	30	37	therapy
O	38	40	in
O	41	49	patients
O	50	54	with
O	55	59	HER2
O	59	60	-
O	60	68	positive
O	69	76	locally
O	77	85	advanced
O	86	88	or
O	89	101	inflammatory
O	102	108	breast
O	109	115	cancer
O	116	129	participating
O	130	132	in
O	133	136	the
O	137	148	NeOAdjuvant
O	149	158	Herceptin
O	159	160	(
O	160	164	NOAH
O	164	165	)
O	166	171	study
O	171	172	.

O	173	175	To
O	176	184	describe
O	185	193	surgical
O	194	202	outcomes
O	203	205	in
O	206	214	patients
O	215	219	with
O	220	224	HER2
O	224	225	-
O	225	233	positive
O	234	241	locally
O	242	250	advanced
O	251	252	(
O	252	256	LABC
O	256	257	)
O	258	260	or
O	261	273	inflammatory
O	274	280	breast
O	281	287	cancer
O	288	289	(
O	289	292	IBC
O	292	293	)
O	294	307	participating
O	308	310	in
O	311	314	the
O	315	326	NeOAdjuvant
O	327	336	Herceptin
O	337	338	(
O	338	342	NOAH
O	342	343	)
O	344	349	study
O	350	351	(
O	351	365	ISRCTN86043495
O	365	366	)
O	366	367	.

O	368	369	A
O	370	375	total
O	376	378	of
B-total-participants	379	382	235
B-eligibility	383	391	patients
I-eligibility	392	396	with
I-eligibility	397	401	HER2
I-eligibility	401	402	-
I-eligibility	402	410	positive
I-eligibility	411	418	disease
O	419	423	were
O	424	434	randomized
O	435	437	to
B-intervention	438	449	neoadjuvant
I-intervention	450	461	trastuzumab
I-intervention	462	466	plus
I-intervention	467	479	chemotherapy
O	480	481	(
O	481	492	doxorubicin
O	493	497	plus
O	498	508	paclitaxel
O	508	509	,
O	510	518	followed
O	519	521	by
O	522	532	paclitaxel
O	532	533	,
O	534	542	followed
O	543	545	by
O	546	562	cyclophosphamide
O	562	563	,
O	564	576	methotrexate
O	577	580	and
O	581	593	fluorouracil
O	593	594	)
O	595	597	or
B-control	598	609	neoadjuvant
I-control	610	622	chemotherapy
I-control	623	628	alone
O	628	629	.

O	630	632	Of
O	633	638	these
O	639	647	patients
O	647	648	,
B-total-participants	649	652	228
O	653	661	received
O	662	667	their
O	668	677	allocated
O	678	687	treatment
O	688	689	(
B-intervention-participants	689	692	115
O	693	701	received
O	702	713	trastuzumab
O	714	718	plus
O	719	731	chemotherapy
O	732	735	and
B-control-participants	736	739	113
O	740	748	received
O	749	761	chemotherapy
O	762	767	alone
O	767	768	)
O	769	772	and
O	773	777	were
O	778	789	potentially
O	790	798	eligible
O	799	802	for
O	803	810	surgery
O	810	811	.

O	812	822	Mastectomy
O	823	826	was
O	827	835	required
O	836	839	for
O	840	843	all
O	844	852	patients
O	853	857	with
O	858	861	IBC
O	862	865	and
O	866	869	was
O	870	881	recommended
O	882	885	for
O	886	889	all
O	890	898	patients
O	899	903	with
O	904	908	LABC
O	908	909	.

O	910	917	However
O	917	918	,
O	919	925	breast
O	925	926	-
O	926	936	conserving
O	937	944	therapy
O	945	950	could
O	951	953	be
O	954	964	considered
O	965	968	for
O	969	977	patients
O	978	982	with
O	983	993	peripheral
O	994	1003	neoplasms
O	1004	1013	measuring
O	1014	1015	â‰¤
O	1016	1017	4
O	1018	1020	cm
O	1021	1023	in
O	1024	1032	diameter
O	1033	1035	at
O	1036	1045	diagnosis
O	1045	1046	,
O	1047	1051	with
O	1052	1053	a
O	1054	1063	favorable
O	1064	1069	ratio
O	1070	1072	of
O	1073	1078	tumor
O	1079	1081	to
O	1082	1088	breast
O	1089	1095	volume
O	1095	1096	,
O	1097	1099	or
O	1100	1102	at
O	1103	1106	the
O	1107	1114	patient
O	1114	1115	'
O	1115	1116	s
O	1117	1124	request
O	1125	1127	if
O	1128	1133	there
O	1134	1137	had
O	1138	1142	been
O	1143	1144	a
O	1145	1149	good
O	1150	1158	response
O	1159	1161	to
O	1162	1171	treatment
O	1171	1172	.

O	1173	1175	As
O	1176	1186	previously
O	1187	1195	reported
O	1195	1196	,
O	1197	1200	the
O	1201	1209	addition
O	1210	1212	of
O	1213	1224	trastuzumab
O	1225	1227	to
O	1228	1239	neoadjuvant
O	1240	1252	chemotherapy
O	1253	1261	improved
O	1262	1265	the
O	1266	1273	overall
O	1273	1274	,
O	1275	1283	complete
O	1284	1287	and
O	1288	1300	pathological
O	1301	1309	complete
O	1310	1318	response
O	1319	1321	to
O	1322	1329	therapy
O	1330	1333	and
O	1334	1347	significantly
O	1348	1356	improved
B-outcome-Measure	1357	1362	event
I-outcome-Measure	1362	1363	-
I-outcome-Measure	1363	1367	free
I-outcome-Measure	1368	1376	survival
O	1377	1378	(
O	1378	1381	the
O	1382	1389	primary
O	1390	1398	endpoint
O	1399	1401	of
O	1402	1405	the
O	1406	1411	study
O	1411	1412	)
O	1412	1413	.

O	1414	1425	Trastuzumab
O	1426	1430	also
O	1431	1438	enabled
O	1439	1443	more
O	1444	1452	patients
O	1453	1455	to
O	1456	1460	have
B-outcome	1461	1467	breast
I-outcome	1468	1478	conserving
I-outcome	1479	1486	surgery
I-outcome	1487	1488	(
I-outcome	1488	1491	BCS
I-outcome	1491	1492	)
O	1493	1494	(
B-iv-bin-percent	1494	1496	23
I-iv-bin-percent	1496	1497	%
O	1498	1504	versus
B-cv-bin-percent	1505	1507	13
I-cv-bin-percent	1507	1508	%
O	1509	1521	respectively
O	1521	1522	)
O	1523	1530	without
O	1531	1533	an
O	1534	1542	apparent
O	1543	1554	detrimental
O	1555	1561	effect
O	1562	1564	on
O	1565	1570	local
O	1571	1578	disease
O	1579	1586	control
O	1587	1588	(
O	1588	1590	no
O	1591	1598	patient
O	1599	1606	treated
O	1607	1611	with
O	1612	1623	trastuzumab
O	1624	1628	plus
O	1629	1641	chemotherapy
O	1642	1645	had
O	1646	1657	experienced
O	1658	1659	a
O	1660	1665	local
O	1666	1676	recurrence
O	1677	1682	after
O	1683	1686	BCS
O	1687	1689	at
O	1690	1693	the
O	1694	1698	time
O	1699	1701	of
O	1702	1710	analysis
O	1710	1711	)
O	1711	1712	.

O	1713	1721	Although
O	1722	1726	this
O	1727	1730	was
O	1731	1734	not
O	1735	1737	an
O	1738	1741	aim
O	1742	1744	of
O	1745	1748	the
O	1749	1754	trial
O	1754	1755	,
O	1756	1767	neoadjuvant
O	1768	1779	trastuzumab
O	1780	1785	given
O	1786	1798	concurrently
O	1799	1803	with
O	1804	1816	chemotherapy
O	1817	1824	enabled
O	1825	1827	23
O	1827	1828	%
O	1829	1831	of
O	1832	1840	patients
O	1841	1845	with
O	1846	1850	HER2
O	1850	1851	-
O	1851	1859	positive
O	1860	1864	LABC
O	1864	1865	/
O	1865	1868	IBC
O	1869	1871	to
O	1872	1877	avoid
O	1878	1888	mastectomy
O	1889	1890	(
O	1890	1899	including
O	1900	1901	a
O	1902	1907	small
O	1908	1914	number
O	1915	1917	of
O	1918	1926	patients
O	1927	1931	with
O	1932	1935	IBC
O	1935	1936	)
O	1936	1937	.
